The increasing use of Real World Evidence (RWE) to inform every part of the drug discovery and commercialisation pathway is clear. That is not say that there are not challenges remaining in how to harness the power of RWE when it emerges from multiple sources with different validation metrics and standards. Used effectively however, leveraging RWE can enhance the discovery of new disease targets and biomarkers; instigate innovation in clinical trial design and where assets are protected to attract investment, aid commercialisation and hence innovative treatments reaching patients. The speakers at this session will discuss how some of these challenges are being addressed, using the field of rare diseases as an exemplar for lessons applicable in all areas.  

Agenda:

15.00 – Registration & Networking
15.30 – Welcome
15.35 - Accessing and utilising rare disease patient data to enable R&D
Soren Demin, PharmaVentures (Moderator)
Ron Jortner, CEO, Aspire Biosciences
15.50 - Standardisation of data collection and sharing to deliver useful RWE to inform clinical trial design
Femida Gwadry-Sridhar, CEO, Pulse Infoframe
16.05 - Clinical Trial Regulation and Transparency Rules - protecting clinical trial-related IP
Ravi Srinivasan, J A Kemp
16.20  - Leveraging RWE in new product commercialisation
Julie Adrian, CEO, Alverium Health
16.35 – Open Q&A with the speakers
17.00 – Networking over drinks & canapes
18.00 – Close

Registration:

This event is free to attend, invite only and is particularly aimed at attendees from:

• Life Science R&D companies
• TechBio companies
• Tech Transfer Offices/Academia
• Investors
• CRO/CDMO companies

To request and invitation, please email Tony Jones directly.